Ramucirumab

Fruquintinib plus paclitaxel significantly improved PFS in patients with advanced gastric or gastroesophageal junction adenocarcinoma, according to results from a phase 3 trial presented during an ASCO Plenary Series session.

Hossein Borghaei, DO, MS, spoke with Healio about findings from the S1800A Lung-MAP substudy and CheckMate 816.

World Lung Cancer Day will be held Aug. 1.

In this video, Ravi Salgia, MD, PhD, discussed findings from two studies presented at ASCO Annual Meeting — one investigating immunotherapy and the other targeted therapy — for the treatment of lung cancer.

In this video, Jia Luo, MD, highlighted a phase 2 randomized study in non-small cell lung cancer presented at ASCO Annual Meeting.

CHICAGO — A new combination therapy benefitted certain patients with immunotherapy-resistant advanced non-small cell lung cancer, according to randomized phase 2 study results presented at ASCO Annual Meeting.

Roy Herbst, MD, PhD, discussed updated toxicity data from the Lung-MAP non-matched sub-study S1800A presented at the virtual ASCO Annual Meeting.

The FDA approved four regimens for non-small cell lung cancer since mid-May.